Theralase Technologies Inc. V.TLT

How many big pharmas and what are they buying

[N0taP00p]

Pfizer is digesting its $43B buy of Seagen (cancer focused monoclonal antibodies).  Merck bought Prometheus for $11B (immunology, non cancer, phase 3 ongoing). That leaves J&J, Amgen, Eli Lilly, Abbvie, Gilead, Novartis, Biogen, GSK, Bristol Myers Squibb , etc. I'm guessing one of them will buy Ferring before they make Adstiladrin available later this year.  With BTD and AA, Theralase will have an immediate target on its back.  If the limited treatments and safety aspects also qualify TLD1433 to be used as an adjuvant therapy, with say BCG or chemo, that target will be much much larger.  

Question is, are these companies even aware of TLTs data?  My bets would be on Novartis or Merck. If TLT shows BTD and AA.  Novartis is more geared for smaller acquisitions at an advanced stage of research,  per an interview I remember seeing. Good weekend, all.  I'm hoping we get to hear that BTD submission is done by the AGM.

[gojotv!]

Real investors aren't interested in selling out for pennies to Big Pharma, but nice post. It gives us a good idea of what TLT would sell for in the bargain basement.

[Infinity]

Getting big pharma in a JV is possibly the best option IMHO.  Outright sale either for cash or stock will most likely be a poor deal for the amount of time, money and effort put into a Novel approach in treating multiple forms of Cancer!!. JV on the other hand would give TLT the much needed resources of Finance, long established relationships with FDA, as well as influencers namely family

[StevenBirch]

We talk about financing, a lot about a possible PP lately because of the trading activity, and about BTD/AA. They, TLT management, have talked about partnering talks that have probably been going on. If the trading is just someone guessing and not really knowing anything then it's possible there could be advanced talks centered on BTD approval which could hopefully mean it all comes together

[Infinity]

 As we all know the last "Follow-up" PP did not gain much attention, largely due to lack of clarity and management not willing to disclose anything beyond bare minimum for understandable reasons....from past  "Settlement" between RDW and OSC that placed Roger in the Penalty box for a very minor miss-statement of our Laser Device's progess made back then. 

[Oilminerdeluxe]

That would be wonderful. They must have something to talk about then :-)

[N0taP00p]

@infinity, StevenBirch et al: Let's hope that's the case ie. they have some upfront cash coming as part of a JV. The PP route will only work if they have new timeline info, and so far, they have not shared enough on that front.   If the FDA can authorize an unapproved Chinese pharmacy to send Cisplatin to relieve the shortage in the US, they surely should be looking to alleviate

[Sosak1]

With every day 100 k on offer, talks are most likly going on. Something is in works.

[Sunvalley]

Good morning Sosak1. I also believe that something is in the works and has been since last November when that flurry of insider action happened. Why did insiders go on a feeding frenzy at that time? Why was the share offering suddenly closed with no explanation? Why did Pfizer terminate their NMIBC trial at that time? Why did TLT grant stock options at that specific time? Why has there seemingly

[Yajne]

I agree SB that the longer it goes, the less likely a PP. I've been thinking about it from the point-of-view of a potential JV partner. IMO the only way TLT gets a great deal before FDA approval for BTD/AA on NMIBC is to include either GBM or NSCLC in the mix, both of which should be getting close to a Ph1 trial application. Under a NDA, a bigPharma potential partner might be shown the lab

[Oilminerdeluxe]

Hope something like that happens asap. Would be nice to not have to worry about empty coffers anymore. If it ends up being just a PP, so be it. Having money is better than having no money. They must be running on frail fumes by now, so perhaps a deal is in the works. At least there is the possibility of it happening. i seem to recall our former CEO said something about end of 23, beginning of 24

[StevenBirch]

Interesting but it would be really hard to assess fair value this early in the GBM and NSCLC process. If we are right and "the longer it goes the less likely there is a PP" that would mean they are fairly confident in getting BTD sometime soon since they need the money. Hopefully this all comes into focus by the time the AGM rolls around.

[99942Apophis]

Actually StevenBirch a rough estimate of fair value can be calculated by the average number of new patients per year with say 2 to 3 treatments. Although just a theoretical calculation it would still be a working base for both Theralase and possible partner to negotiate the partnership. Beyond new patients are also people who are currently being treated and might migrate to Theralase's